2001
Summary Statement: The Sygen® (GM-1 Ganglioside) Clinical Trial in Acute Spinal Cord Injury
Fehlings M, Bracken M. Summary Statement: The Sygen® (GM-1 Ganglioside) Clinical Trial in Acute Spinal Cord Injury. Spine 2001, 26: s99-s100. PMID: 11805615, DOI: 10.1097/00007632-200112151-00016.Commentaries, Editorials and Letters
1990
A Randomized, Controlled Trial of Methylprednisolone or Naloxone in the Treatment of Acute Spinal-Cord Injury
Bracken M, Shepard M, Collins W, Holford T, Young W, Baskin D, Eisenberg H, Flamm E, Leo-Summers L, Maroon J, Marshall L, Perot P, Piepmeier J, Sonntag V, Wagner F, Wilberger J, Winn H. A Randomized, Controlled Trial of Methylprednisolone or Naloxone in the Treatment of Acute Spinal-Cord Injury. New England Journal Of Medicine 1990, 322: 1405-1411. PMID: 2278545, DOI: 10.1056/nejm199005173222001.Peer-Reviewed Original ResearchConceptsAcute spinal cord injurySpinal cord injuryNeurologic recoverySafety of methylprednisoloneSystematic neurological examinationPlacebo-controlled trialHours of injuryMajor morbidityNeurologic outcomeControlled TrialsNeurological examinationIncomplete lesionsMotor functionMethylprednisoloneNaloxonePatientsBody weightSensory functionInjuryPlaceboInfusionBolusEffective remainsTreatmentDose